Glomerular Injury of Preeclampsia
|ClinicalTrials.gov Identifier: NCT00275158|
Recruitment Status : Completed
First Posted : January 11, 2006
Last Update Posted : January 14, 2010
|Condition or disease||Intervention/treatment||Phase|
|Pre-Eclampsia||Drug: L-Arginine Supplementation||Not Applicable|
OBJECTIVE: To assess the benefit of L-arginine, the precursor to nitric oxide (NO), to blood pressure and recovery of the glomerular lesion in pre-eclampsia.
METHODS: 45 women with pre-eclampsia were randomized to receive either L-arginine or placebo until day 10 post-partum. Primary outcome measures including MAP, glomerular filtration rate and proteinuria were assessed on the third and tenth days postpartum by inulin clearance and albumin-to-creatinine (A/C) ratio. NO, cyclic guanosine 3'5' monophosphate (cGMP), endothelin-1 (ET) and asymmetric-dimethyl-arginine (ADMA) and arginine levels were assayed prior to delivery, on the third and tenth day postpartum. Healthy gravid women provided control values. Assuming a standard deviation of 10 mmHg, the study was powered to detect a 10 mmHg difference in MAP (alpha 0.05, beta 0.20) between the study groups.
RESULTS: No significant differences existed between the groups with pre-eclampsia prior to randomization. Compared to the gravid control group, women with pre-eclampsia did not reveal significantly depressed levels of serum arginine, but did reveal significantly increased serum levels of ET, cGMP and ADMA prior to delivery. Despite a significant increase in serum arginine levels due to treatment, no differences were found in the levels of NO, ET, cGMP or ADMA between the two groups with pre-eclampsia. Further, there were no significant differences in any of the primary outcome measures with both groups demonstrating equivalent improvements in both blood pressure and proteinuria.
CONCLUSION: Blood pressure and kidney function improve markedly in pre-eclampsia by the tenth day postpartum. L-arginine supplementation does not hasten this recovery.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||45 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Effect of L-Arginine Therapy on the Glomerular Injury of Pre-Eclampsia: A Randomized Controlled Trial|
|Study Start Date :||January 2000|
|Actual Study Completion Date :||December 2003|
- Mean Arterial Pressure
- Glomerular Filtration Rate (inulin clearance)
- Proteinuria (albumin to creatinine ratio)
- Vasoactive hormone levels - Nitric Oxide, Endothelin, cGMP, ADMA
- Neonatal Outcomes
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00275158
|United States, California|
|Stanford University Medical Center|
|Stanford, California, United States, 94305|
|Principal Investigator:||Bryan D Myers, MD||Stanford University|